SCHEMBL469972

SCHEMBL469972

C=CCNC(=S)N/N=C1\C(=O)Nc2ccccc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.43
KMT2A Q03164 3/20 0.43
MAPT P10636 2/20 0.43
MEN1 O00255 2/20 0.43
LMNA P02545 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 3/20 0.42
KCNH2 Q12809 1/20 0.42
GAA P10253 2/20 0.42
LRRK2 Q5S007 5/20 0.42
IDO1 P14902 2/20 0.42
KDR P35968 2/20 0.41
POLB P06746 2/20 0.40
KDM4E B2RXH2 1/20 0.40
PTBP1 P26599 1/20 0.40
OPRK1 P41145 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL455445 0.83 ALDH1A1 (0.42) TDP1KMT2AMAPTMEN1LMNA
SCHEMBL10084820 0.81 TDP1 (0.43) TDP1KMT2AMAPTMEN1L3MBTL1
SCHEMBL469854 0.80 KDR (0.56) KMT2AMAPTMEN1ALDH1A1GAA
SCHEMBL10084818 0.79 KMT2A (0.53) TDP1KMT2AMAPTMEN1LMNA
SCHEMBL10084821 0.76 KMT2A (0.58) TDP1KMT2AMAPTMEN1ALDH1A1
SCHEMBL98437 0.76 KMT2A (0.58) TDP1KMT2AMAPTMEN1ALDH1A1
SCHEMBL10084866 0.76 LRRK2 (0.53) KMT2AMAPTALDH1A1GAALRRK2
SCHEMBL10085722 0.76 KDR (0.61) MAPTNPSR1ALDH1A1LRRK2IDO1
SCHEMBL18974340 0.76 KDR (0.49) KMT2AMAPTMEN1GAALRRK2
SCHEMBL31491999 0.76 LRRK2 (0.53) KMT2AMAPTALDH1A1GAALRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2240175-B1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY US GOV HEALTH & HUMAN SERV (US) 2013-01-02 EP disclosed
WO-2012033601-A1 THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2012-03-15 WO disclosed
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY INSTITUTE OF ENZYMOLOGY, BIOLOGICAL RESEARCH CENTER, HUNGARIAN ACADEMY OF SCIENCES (HU) 2010-12-16 US disclosed
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY INSTITUTE OF ENZYMOLOGY, BIOLOGICAL RESEARCH CENTER, HUNGARIAN ACADEMY OF SCIENCES (HU) 2010-12-16 US disclosed
WO-2009102433-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY ABCC1, ABCB1, ABCC2 TDP1 2071/4885KMT2A 4279/4885MAPT 4584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.